The Challenge

Biohazardous waste can expose individuals, not directly involved with preparation or administration, to dangerous chemicals.

All materials that come in contact with hazardous drugs and patient waste such as vials, intravenous sets, syringes, gloves, gowns, bedpans, and bed linens should be handled as hazardous. In fact, housekeepers who clean the infusion area and remove waste have been found to have drug in their urine, documenting uptake from a contaminated area.1 All waste from the preparation and administration of hazardous drugs should be segregated and disposed of according to hospital policy and applicable state and federal regulations.2,3,4  Reducing this waste significantly lowers the chance of dangerous exposure to hazardous oncology drugs, and also decreases hazardous waste removal costs estimated at $.40/pound based on the Baxa Corporation Star Center® course on the Safe Handling and Preparation of Hazardous Drugs. 

The cost of implementing a CSTD into clinical practice is a deciding factor in the purchasing process.

As economic pressures increase, procurement decisions can no longer rely solely on clinical efficacy studies that fail to assess cost-effectiveness. An evaluation of implementation costs is essential when comparing commercially available CSTDs.

Our Solution

The ChemoClave® CSTD can help facilities significantly reduce biohazardous waste.

The ChemoClave CSTD is comprised of a selection of vial adapters that mechanically prohibit the transfer and escape of environmental contaminants, including the Genie® needlefree CSTD vial access device with an internal balloon that automatically equalizes drug vial pressure when extracting hazardous medications from vials; a selection of needlefree bag spikes; and primary add-on and administration sets featuring the Spiros® CSTD male luer.

As a result of the simplicity of the system itself, ChemoClave CSTD generates the second least amount of biohazardous waste than any other commercially available CSTD. A prospective study of the waste implications of available CSTDs showed that the ChemoClave CSTD allows a high-volume cancer center to reduce biohazardous waste by nearly 2,300 pounds each year. Calculations were based on the amount of waste generated by each of the systems if used at a single high-volume oncology facility/hospital preparing 1276 monthly infusions over twelve months for a total of 15,312 infusions annually.5
 

total-waste.png

The  ChemoClave CSTD costs less to implement than any other commercially available CSTD.

A recent study looked at the costs associated with implementing various CSTD systems throughout the clinical delivery continuum, including the preparation, transportation, administration, and disposal of hazardous drugs. Real cost savings was estimated to be as much as $307,000 a year with the ChemoClave CSTD for a single high-volume cancer facility as compared to other CSTD systems.5 Another study that analyzed costs of available CSTDs estimated that using the ChemoClave CSTD could save a facility between $57.50 and $112.50 for every 100 chemotherapy bags administered.
 

Total -cost

References

* Calculations are based on a single, high-volume oncology facility/hospital preparing 100 mixes a day over 365 working days, for a total of 36,500 mixes annually. Texium/SmartSite is marketed as a closed system, not a CSTD.

† Component cost may vary slightly due to manufacturing price changes, contract pricing, and/or volume discount pricing. Texium/SmartSite is marketed as a closed system, not a CSTD.

  1. Eisenberg et al. Journal of Infusion Nursing: January 2009 - Volume 32 - Issue 1 - p 23-32.
  2. National Institute for Occupational Safety and Health. NIOSH Alert: preventing occupational exposures to antineoplastic and other hazardous drugs in the health care setting. Centers for Disease Control and Prevention, National Institute for Occupation Safety and Health, DHHS (NIOSH) Publication No. 2004-165. Washington, DC: U.S. Department of Health and Human Services.
  3. Smith CA. Managing pharmaceutical waste: what pharmacists should know. J Pharm Soc WI 2002; November/December: 17-22.
  4. International Society of Oncology Pharmacy Practicioners Standards Committee. ISOPP standards of practice. Section 2 - Transport of cytotoxics. J Oncol Pharm Pract. 2007; 13 Suppl:1-81.
  5. Barnachea L, Lee T, Gitler J, Saria M. Presented at the California Society of Health System Pharmacists (CSHP), November 4, 2011
  6. Saria M et al. The Cost of Safety: Closed System Transfer Devices, Abstract Accepted at the International Forum on Quality & Safety in Healthcare, April 2011, Amsterdam NL.